Lung cancer screening at any price?

Journal of the American Medical Association

Volumn 289, Issue 3, 2003, Pages 357-358

  Grann, Victor R ^a,b   Neugut, Alfred I ^a,b  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER MORTALITY; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; EDITORIAL; HEALTH CARE COST; HUMAN; LUNG CANCER; MEDICAL RESEARCH; MORBIDITY; POLICY; PRIORITY JOURNAL; SMOKING; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

EID: 0037438929     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.3.357     Document Type: Editorial

References (20)

1. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
2. Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40-49 years of age. Ann Intern Med. 1997;127:955-965.
3. Weinstein MC, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health. 1985;6:41-63.
4. Goldman L, Weinstein MC, Goldman EA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991;265:1145-1151.
5. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
6. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care. 1995;33: 828-841.
7. Weiss W. Cigarette smoking and lung cancer trends: a light at the end of the tunnel? Chest. 1997;111:1414-1416.
8. Burns DM. Primary prevention, smoking, and smoking cessation: implications for future trends in lung cancer prevention. Cancer. 2000;89(suppl 11):2506-2509.
9. Henschke CI, McCauley DJ, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999;354: 99-105.
10. Sobue T, Moriyama N, Kaneko M, et al. Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol. 2002;20:911-920.
11. Sone S, Li F, Yang ZG, Honda T, et al. Results of three-year mass screening programmed for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer. 2001;84:25-32.
12. Henschke CI, Yankelevitz DF. CT screening for lung cancer. Radiol Clin North Am. 2000;38:487-495.
13. Henschke CI, Naidich DP, Yankelevitz DF, et al. Early lung cancer action project: initial findings on repeat screenings. Cancer. 2001;92:153-159.
14. Patz EF Jr, Black WC, Goodman PC. CT screening for lung cancer: not ready for routine practice. Radiology. 2001;221:587-591.
15. Marcus PM. Lung cancer screening: an update. J Clin Oncol. 2001;19(suppl 18):83S-86S.
16. Boughton B. Large screening trial launched by NCI. Lancet Oncol. 2002;3:647.
17. Kramer BS. Spiral computed tomography screening: study begins to determine its efficacy in lung cancer prevention. West J Med. 2001;174:230-231.
18. Lee TH, Brennan TA. Direct-to-consumer marketing of high-technology screening tests. N Engl J Med. 2002;346:529-531.
19. Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA. 2003;289:313-322.
20. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000;18:3302-3317.